Genomic Cancer Medicine Lab


Graphical user interface for simultaneous profiling of activity patterns in multiple neuronal subclasses
Parrish, R. R.; Grady, J.; Codadu, N. K.; Racca, C.; Trevelyan, A. J.
Data in Brief 20:226-233, 2018
Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report
Lau, B.; Menzies, A. M.; Joshua, A. M.
Annals Of Oncology 32(2):280-282, 2021
Wiki-based clinical practice guidelines for the management of adult onset sarcoma: a new paradigm in sarcoma evidence
Neuhaus, S. J.
; Thomas, D.
; Desai, J.
; Vuletich, C.
; von Dincklage, J.
; Olver, I.;
Sarcoma 2015:614179, 2015
Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma
Mirabello, L.; Zhu, B.; Koster, R.; Karlins, E.; Dean, M.; Yeager, M.; Gianferante, M.; Spector, L. G.; Morton, L. M.; Karyadi, D.; Robison, L. L.; Armstrong, G. T.; Bhatia, S.; Song, L.; Pankratz, N.; Pinheiro, M.; Gastier-Foster, J. M.; Gorlick, R.; de Toledo, S. R. C.; Petrilli, A. S.; Patino-Garcia, A.; Lecanda, F.; Gutierrez-Jimeno, M.; Serra, M.; Hattinger, C.; Picci, P.; Scotlandi, K.; Flanagan, A. M.; Tirabosco, R.; Amary, M. F.; Kurucu, N.; Ilhan, I. E.; Ballinger, M. L.; Thomas, D. M.; Barkauskas, D. A.; Mejia-Baltodano, G.; Valverde, P.; Hicks, B. D.; Zhu, B.; Wang, M.; Hutchinson, A. A.; Tucker, M.; Sampson, J.; Landi, M. T.; Freedman, N. D.; Gapstur, S.; Carter, B.; Hoover, R. N.; Chanock, S. J.; Savage, S. A.
JAMA Oncology 6(5):724-734, 2020
The growing problem of benign connective tissue tumours
Thomas, D. M.;
LANCET ONCOLOGY 16(8):879-880, 2015
Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer
Cilento, M. A.; Poplawski, N. K.; Paramasivam, S.; Thomas, D. M.; Kichenadasse, G.
Journal of the National Comprehensive Cancer Network 19(11):1212-1217, 2021
Germline RET variants underlie a subset of paediatric osteosarcoma
Kovac, M.; Woolley, C.; Ribi, S.; Blattmann, C.; Roth, E.; Morini, M.; Kovacova, M.; Ameline, B.; Kulozik, A.; Bielack, S.; Hartmann, W.; Ballinger, M. L.; Thomas, D. M.; Tomlinson, I.; Nathrath, M.; Heinimann, K.; Baumhoer, D.
A randomized phase II trial of geriatric assessment and management for older cancer patients
Puts, M. T. E.; Sattar, S.; Kulik, M.; MacDonald, M. E.; McWatters, K.; Lee, K.; Brennenstuhl, S.; Jang, R.; Amir, E.; Krzyzanowska, M. K.; Joshua, A. M.; Monette, J.; Wan-Chow-Wah, D.; Alibhai, S. M. H.
SUPPORTIVE CARE IN CANCER :doi: 10.1007/s00520-017-3820-7, 2018
Cancer Patient Experience of Uncertainty While Waiting for Genome Sequencing Results
Bartley, N.; Napier, C. E.; Butt, Z.; Schlub, T. E.; Best, M. C.; Biesecker, B. B.; Ballinger, M. L.; Butow, P.
Frontiers in Psychology 12:647502, 2021
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer
Wong, M.; Mayoh, C.; Lau, L. M. S.; Khuong-Quang, D. A.; Pinese, M.; Kumar, A.; Barahona, P.; Wilkie, E. E.; Sullivan, P.; Bowen-James, R.; Syed, M.; Martincorena, I.; Abascal, F.; Sherstyuk, A.; Bolanos, N. A.; Baber, J.; Priestley, P.; Dolman, M. E. M.; Fleuren, E. D. G.; Gauthier, M. E.; Mould, E. V. A.; Gayevskiy, V.; Gifford, A. J.; Grebert-Wade, D.; Strong, P. A.; Manouvrier, E.; Warby, M.; Thomas, D. M.; Kirk, J.; Tucker, K.; O'Brien, T.; Alvaro, F.; McCowage, G. B.; Dalla-Pozza, L.; Gottardo, N. G.; Tapp, H.; Wood, P.; Khaw, S. L.; Hansford, J. R.; Moore, A. S.; Norris, M. D.; Trahair, T. N.; Lock, R. B.; Tyrrell, V.; Haber, M.; Marshall, G. M.; Ziegler, D. S.; Ekert, P. G.; Cowley, M. J.
NATURE MEDICINE 26(11):1742-1753, 2020
Cancer 2015: a longitudinal, whole of system study of genomic cancer medicine
Thomas, D.M.; Fox, S.; Lorgelly, P.K.; Ashley, D.; Richardson, G.; Lipton, L.; Parisot, J. P.; Lucas, M.; McNeil, J.; Wright M for the Cancer 2015 Investigators, .;
DRUG DISCOVERY TODAY 20(12):1429-32, 2015
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
Ballinger, M. L.; Goode, D. L.; Ray-Coquard, I.; James, P. A.; Mitchell, G.; Niedermayr, E.; Puri, A.; Schiffman, J. D.; Dite, G. S.; Cipponi, A.; Maki, R. G.; Brohl, A. S.; Myklebost, O.; Stratford, E. W.; Lorenz, S.; Ahn, S. M.; Ahn, J. H.; Kim, J. E.; Shanley, S.; Beshay, V.; Randall, R. L.; Judson, I.; Seddon, B.; Campbell, I. G.; Young, M. A.; Sarin, R.; Blay, J. Y.; O'Donoghue, S. I.; Thomas, D. M.; International Sarcoma Kindred, Study;
LANCET ONCOLOGY 17(9):1261-71, 2016
PARP Inhibitors in Melanoma-An Expanding Therapeutic Option?
Chan, W. Y.; Brown, L. J.; Reid, L.; Joshua, A. M.
Cancers (Basel) 13(18):4520, 2021
Therapeutic implications of germline genetic findings in cancer
Thavaneswaran, S.; Rath, E.; Tucker, K.; Joshua, A. M.; Hess, D.; Pinese, M.; Ballinger, M. L.; Thomas, D. M.
Nature Reviews Clinical Oncology 16(6):386-396, 2019
Penetrance of different cancer types in families with Li-Fraumeni syndrome: A validation study using multicenter cohort.
Shin, S. J.; Dodd-Eaton, E. B.; Peng, G.; Bojadzieva, J.; Chen, J.; Amos, C. I.; Frone, M. N.; Khincha, P. P.; Mai, P. L.; Savage, S. A.; Ballinger, M. L.; Thomas, D. M.; Yuan, Y.; Strong, L. C.; Wang, W.
CANCER RESEARCH 80(2):354-360, 2020
Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis
Ballinger, M. L.; Best, A.; Mai, P. L.; Khincha, P. P.; Loud, J. T.; Peters, J. A.; Achatz, M. I.; Chojniak, R.; Balieiro da Costa, A.; Santiago, K. M.; Garber, J.; O'Neill, A. F.; Eeles, R. A.; Evans, D. G.; Bleiker, E.; Sonke, G. S.; Ruijs, M.; Loo, C.; Schiffman, J.; Naumer, A.; Kohlmann, W.; Strong, L. C.; Bojadzieva, J.; Malkin, D.; Rednam, S. P.; Stoffel, E. M.; Koeppe, E.; Weitzel, J. N.; Slavin, T. P.; Nehoray, B.; Robson, M.; Walsh, M.; Manelli, L.; Villani, A.; Thomas, D. M.; Savage, S. A.
JAMA Oncology 3(12):1634-1639, 2017
Cancer stemness, intratumoral heterogeneity, and immune response across cancers
Miranda, A.; Hamilton, P. T.; Zhang, A. W.; Pattnaik, S.; Becht, E.; Mezheyeuski, A.; Bruun, J.; Micke, P.; de Reynies, A.; Nelson, B. H.
Adding the 'medicines' back into personalized medicine to improve cancer treatment outcomes
Martin, J. H.; Phillips, E.; Thomas, D.; Somogyi, A. A.;
Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging
Ballinger, M. L.; Ferris, N. J.; Moodie, K.; Mitchell, G.; Shanley, S.; James, P. A.; Thomas, D. M.
JAMA Oncology 3(12):1735-1736, 2017
Treatment outcomes from 68GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative PSMA PET
Emmett, L.; Van Leeuwen, P.; Nandurkar, R.; Scheltema, M. J.; Cusick, T.; Hruby, G.; Kneebone, A.; Eade, T.; Fogarty, G.; Jagavkar, R.; Nguyen, Q.; Ho, B.; Joshua, A. M.; Stricker, P.
JOURNAL OF NUCLEAR MEDICINE 58(12):1972-1976, 2017
Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study
Puts, M. T.; Sattar, S.; McWatters, K.; Lee, K.; Kulik, M.; MacDonald, M. E.; Jang, R.; Amir, E.; Krzyzanowska, M. K.; Leighl, N.; Fitch, M.; Joshua, A. M.; Warde, P.; Tourangeau, A. E.; Alibhai, S. M.
SUPPORTIVE CARE IN CANCER 25(3):879-886, 2017
Patient perspectives on molecular tumor profiling: "Why wouldn't you?"
Best, M. C.; Bartley, N.; Jacobs, C.; Juraskova, I.; Goldstein, D.; Newson, A. J.; Savard, J.; Meiser, B.; Ballinger, M.; Napier, C.; Thomas, D.; Biesecker, B.; Butow, P.
BMC Cancer 19(1):753, 2019
Sequencing Strategies for Fusion Gene Detection
Heyer, E. E.; Blackburn, J.
BIOESSAYS 42(7):e2000016, 2020
""Cancer 2015"": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic
Parisot, J. P.; Thorne, H.; Fellowes, A.; Doig, K.; Lucas, M.; McNeil, J. J.; Doble, B.; Dobrovic, A.; John, T.; James, P. A.; Lipton, L.; Ashley, D.; Hayes, T.; McMurrick, P.; Richardson, G.; Lorgelly, P.; Fox, S. B.; Thomas, D. M.;
Journal of Personalized Medicine 5(4):354-369, 2015
Family communication about genomic sequencing: A qualitative study with cancer patients and relatives
Smit, A. K.; Bartley, N.; Best, M. C.; Napier, C. E.; Butow, P.; Newson, A. J.; Tucker, K.; Ballinger, M. L.; Thomas, D. M.; Jacobs, C.; Meiser, B.; Goldstein, D.; Savard, J.; Juraskova, I.; PiGeOn authorship, group
A quantitative model to predict pathogenicity of missense variants in the TP53 gene
Fortuno, C.; Cipponi, A.; Ballinger, M. L.; Tavtigian, S. V.; Olivier, M.; Ruparel, V.; Haupt, Y.; Haupt, S.; Study, I. S. K.; Tucker, K.; Spurdle, A. B.; Thomas, D. M.; James, P. A.
HUMAN MUTATION 40(6):788-800, 2019
Mitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinson's disease
Reeve, A. K.; Grady, J. P.; Cosgrave, E. M.; Bennison, E.; Chen, C.; Hepplewhite, P. D.; Morris, C. M.
NPJ Parkinson's Disease 4:9, 2018
Trials and tribulations: improving outcomes for adolescents and young adults with rare and low survival cancers
Walczak, A.; Patterson, P.; Thomas, D.
Estimating TP53 mutation carrier probability in families with Li-Fraumeni syndrome using LFSPRO
Peng, G.; Bojadzieva, J.; Ballinger, M. L.; Li, J.; Blackford, A. L.; Mai, P. L.; Savage, S. A.; Thomas, D. M.; Strong, L. C.; Wang, W.
The architecture and evolution of cancer neochromosomes
Garsed, D..W.
; Marshall, O. J.
; Corbin, V.D.A.
; Hsu, A.
; Di Stefano, A. L.
; Schroder, J.
; Li, J.
; Feng, Z-P.
; Kim, B.W.
; Kowarsky, M.
; Lansdell, B.
; Brookwell, R.
; Myklebost, O.
; Meza-Zepeda, L.
; Holloway, A.J.
; Pedeutour, F.
; Choo, K.H.A.
; Damore, M. A.
; Deans, A. J.
; Papenfuss, A. T.
; Thomas, D. M.;
CANCER CELL 26:653-667, 2014
Simultaneous profiling of activity patterns in multiple neuronal subclasses
Parrish, R. R.; Grady, J.; Codadu, N. K.; Trevelyan, A. J.; Racca, C.
Rapid modulation of PSMA expression by androgen deprivation: Serial (68)Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade
Emmett, L.; Yin, C.; Crumbaker, M.; Hruby, G.; Kneebone, A.; Epstein, R.; Nguyen, Q.; Hickey, A.; Ihsheish, N.; O'Neill, G.; Horvath, L.; Chalasani, V.; Stricker, P.; Joshua, A. M.
The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling.
Best, M.; Newson, A. J.; Meiser, B.; Juraskova, I.; Goldstein, D.; Tucker, K.; Ballinger, M. L.; Hess, D.; Schlub, T. E.; Biesecker, B.; Vines, R.; Vines, K.; Thomas, D.; Young, M. A.; Savard, J.; Jacobs, C.; Butow, P.
BMC Cancer 18(1):389, 2018
Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An assessment of existing and newly developed algorithms
Woodcock, F.; Doble, B.; Cancer 2015 Consortium.
MEDICAL DECISION MAKING 38(8):954-967, 2018
A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma
Lewin, J.
; Khamly, K. K.
; Young, R. J.
; Mitchell, C.
; Hicks, R. J.
; Toner, G. C.
; Ngan, S. Y.
; Chander, S.
; Powell, G. J.
; Herschtal, A.
; Te Marvelde, L.
; Desai, J.
; Choong, P. F.
; Stacker, S. A.
; Achen, M. G.
; Ferris, N.
; Fox, S.
; Slavin, J.
; Thomas, D. M.:
British Journal of Cancer 111(12):2254-2261, 2014
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
Demetri, G. D.; Antonescu, C. R.; Bjerkehagen, B.; Bovee, Jvmg; Boye, K.; Chacon, M.; Dei Tos, A. P.; Desai, J.; Fletcher, J. A.; Gelderblom, H.; George, S.; Gronchi, A.; Haas, R. L.; Hindi, N.; Hohenberger, P.; Joensuu, H.; Jones, R. L.; Judson, I.; Kang, Y. K.; Kawai, A.; Lazar, A. J.; Le Cesne, A.; Maestro, R.; Maki, R. G.; Martin, J.; Patel, S.; Penault-Llorca, F.; Premanand Raut, C.; Rutkowski, P.; Safwat, A.; Sbaraglia, M.; Schaefer, I. M.; Shen, L.; Serrano, C.; Schoffski, P.; Stacchiotti, S.; Sundby Hall, K.; Tap, W. D.; Thomas, D. M.; Trent, J.; Valverde, C.; van der Graaf, W. T. A.; von Mehren, M.; Wagner, A.; Wardelmann, E.; Naito, Y.; Zalcberg, J.; Blay, J. Y.
Annals Of Oncology 31(11):1506-1517, 2020
Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression
Emmett, L.; Crumbaker, M.; Ho, B.; Willowson, K.; Eu, P.; Ratnayake, L.; Epstein, R.; Blanksby, A.; Horvath, L.; Guminski, A.; Mahon, K.; Gedye, C.; Yin, C.; Stricker, P.; Joshua, A. M.
Clinical Genitourinary Cancer 17(1):15-22, 2019
Patient experience of uncertainty in cancer genomics: a systematic review
Bartley, N.; Napier, C.; Best, M.; Butow, P.
GENETICS IN MEDICINE 22(9):1450-1460, 2020
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
Lin, F. P.; Thavaneswaran, S.; Grady, J. P.; Ballinger, M.; Kansara, M.; Oakes, S. R.; Desai, J.; Lee, C. K.; Simes, J.; Thomas, D. M.
NPJ Precision Oncology 5(1):58, 2021
Molecular markers guiding thyroid cancer management
Nylen, C.; Mechera, R.; Marechal-Ross, I.; Tsang, V.; Chou, A.; Gill, A. J.; Clifton-Bligh, R. J.; Robinson, B. G.; Sywak, M. S.; Sidhu, S. B.; Glover, A. R.
Cancers 12(8):2164, 2020
Advanced cancer patient preferences for receiving molecular profiling results
Best, M.; Butow, P.; Jacobs, C.; Juraskova, I.; Savard, J.; Meiser, B.; Goldstein, D.; Ballinger, M.; Bartley, N.; Napier, C.; Davies, G.; Thomas, D.; Tucker, K.; Schlub, T.; Newson, A. J.; PiGeOn Project, .
PSYCHO-ONCOLOGY 29(10):1533-1539, 2020
Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L
Lorgelly, P. K.; Doble, B.; Rowen, D.; Brazier, J.; Cancer 2015 investigators
QUALITY OF LIFE RESEARCH 26(5):1163-1176, 2017
Etiologic, environmental and inherited risk factors in sarcomas
Thomas, D. M.
; Ballinger, M. L.;
The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer
Best, M.; Newson, A. J.; Meiser, B.; Juraskova, I.; Goldstein, D.; Tucker, K.; Ballinger, M. L.; Hess, D.; Schlub, T. E.; Biesecker, B.; Vines, R.; Vines, K.; Thomas, D.; Young, M. A.; Savard, J.; Jacobs, C.; Butow, P.
BMC Cancer 18(1):454, 2018
Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?
McBride, K. A.; Ballinger, M. L.; Schlub, T. E.; Young, M. A.; Tattersall, M. H.; Kirk, J.; Eeles, R.; Killick, E.; Walker, L. G.; Shanley, S.; Thomas, D. M.; Mitchell, G.
Familial Cancer 16(3):423-432, 2017
Exceptional response to 177Lutetium Prostate-Specific Membrane Antigen in prostate cancer harboring DNA repair defects
Crumbaker, Megan; Emmett, Louise; Horvath, Lisa G.; Joshua, Anthony M.
JCO Precision Oncology (3):1-5, 2019
Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers
Thavaneswaran, S.; Sebastian, L.; Ballinger, M.; Best, M.; Hess, D.; Lee, C. K.; Sjoquist, K. M.; Hague, W. E.; Butow, P. N.; Simes, R. J.; Thomas, D.
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
Dancsok, A. R.; Setsu, N.; Gao, D.; Blay, J. Y.; Thomas, D.; Maki, R. G.; Nielsen, T. O.; Demicco, E. G.
MODERN PATHOLOGY 32(12):1772-1785, 2019
Enzalutamide with standard first-line therapy in metastatic prostate cancer
Davis, I. D.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Sweeney, C. J.
Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients
Koster, R.; Panagiotou, O. A.; Wheeler, W. A.; Karlins, E.; Gastier-Foster, J. M.; Caminada de Toledo, S. R.; Petrilli, A. S.; Flanagan, A. M.; Tirabosco, R.; Andrulis, I. L.; Wunder, J. S.; Gokgoz, N.; Patino-Garcia, A.; Lecanda, F.; Serra, M.; Hattinger, C.; Picci, P.; Scotlandi, K.; Thomas, D. M.; Ballinger, M. L.; Gorlick, R.; Barkauskas, D. A.; Spector, L. G.; Tucker, M.; Belynda, D. H.; Yeager, M.; Hoover, R. N.; Wacholder, S.; Chanock, S. J.; Savage, S. A.; Mirabello, L.
PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma
Scheinberg, T.; Lomax, A.; Tattersall, M.; Thomas, D.; McCowage, G.; Sullivan, M.; Karim, R.; Luk, P. P.; Mahar, A.; Bonar, F.; Bhadri, V. A.
Cancer Reports 13:e1327, 2021
Prophylactic central lymph node dissection informs the decision of radioactive iodine ablation in papillary thyroid cancer
Nylen, C.; Eriksson, F. B.; Yang, A.; Aniss, A.; Turchini, J.; Learoyd, D.; Robinson, B. G.; Gill, A. J.; Clifton-Bligh, R. J.; Sywak, M. S.; Glover, A. R.; Sidhu, S. B.
AMERICAN JOURNAL OF SURGERY 221(5):886-892, 2021
Clinical implications of genomics for cancer risk genetics.
Thomas, D. M.; James, P.A.; Ballinger, M. L.;
LANCET ONCOLOGY 16:e303-308, 2015
Phosphoproteomic profiling reveals ALK and MET as novel actionable targets across synovial sarcoma subtypes
Fleuren, E. D. G.; Vlenterie, M.; van der Graaf, W.; Hillebrandt-Roeffen, M. H. S.; Blackburn, J.; Ma, X.; Chan, H.; Magias, M. C.; van Erp, A.; van Houdt, L.; Cebeci, S.; van de Ven, A.; Flucke, U. E.; Heyer, E. E.; Thomas, D. M.; Lord, C. J.; Marini, K. D.; Vaghjiani, V.; Mercer, T.; Cain, J. E.; Wu, J.; Versleijen-Jonkers, Y. M. H.; Daly, R. J.
CANCER RESEARCH 77(16):4279-4292, 2017
Assessment of the value of tumor variation profiling perceived by patients with cancer
Butow, P.; Davies, G.; Napier, C. E.; Schlub, T.; Best, M. C.; Bartley, N.; Juraskova, I.; Meiser, B.; Ballinger, M. L.; Biesecker, B.; Goldstein, D.; Thomas, D. M.; PiGeOn, Project
JAMA Network Open 3(5):e204721, 2020
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Hansen, A. R.; Tannock, I. F.; Templeton, A.; Chen, E.; Evans, A.; Knox, J.; Prawira, A.; Sridhar, S. S.; Tan, S.; Vera-Badillo, F.; Wang, L.; Wouters, B. G.; Joshua, A. M.
ONCOLOGIST 24(9):1188-1194, 2019
MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer
Cipponi, A.; Goode, D. L.; Bedo, J.; McCabe, M. J.; Pajic, M.; Croucher, D. R.; Rajal, A. G.; Junankar, S. R.; Saunders, D. N.; Lobachevsky, P.; Papenfuss, A. T.; Nessem, D.; Nobis, M.; Warren, S. C.; Timpson, P.; Cowley, M.; Vargas, A. C.; Qiu, M. R.; Generali, D. G.; Keerthikumar, S.; Nguyen, U.; Corcoran, N. M.; Long, G. V.; Blay, J. Y.; Thomas, D. M.
SCIENCE 368(6495):1127-1131, 2020
Managing ocular surface neoplasia without biopsy: The end of pathology as we know it?
Conway, M. R.; Cherepanoff, S.; Josua, A. M.
BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis
Kalachand, R. D.; Stordal, B.; Madden, S.; Chandler, B.; Cunningham, J.; Goode, E. L.; Ruscito, I.; Braicu, E. I.; Sehouli, J.; Ignatov, A.; Yu, H.; Katsaros, D.; Mills, G. B.; Lu, K. H.; Carey, M. S.; Timms, K. M.; Kupryjanczyk, J.; Rzepecka, I. K.; Podgorska, A.; McAlpine, J. N.; Swisher, E. M.; Bernards, S. S.; O'Riain, C.; O'Toole, S.; O'Leary, J. J.; Bowtell, D. D.; Thomas, D. M.; Prieske, K.; Joosse, S. A.; Woelber, L.; Chaudhry, P.; Hafner, N.; Runnebaum, I. B.; Hennessy, B. T.
JNCI-Journal of the National Cancer Institute 112(12):1190-1203, 2020
Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas
Dancsok, A. R.; Gao, D.; Lee, A. F.; Steigen, S. E.; Blay, J. Y.; Thomas, D. M.; Maki, R. G.; Nielsen, T. O.; Demicco, E. G.
Oncoimmunology 9(1):1747340, 2020
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Liang, Y.; Jeganathan, S.; Marastoni, S.; Sharp, A.; Figueiredo, I.; Marcellus, R.; Mawson, A.; Shalev, Z.; Pesic, A.; Sweet, J.; Guo, H.; Uehling, D.; Gurel, B.; Neeb, A.; He, H. H.; Montgomery, B.; Koritzinsky, M.; Oakes, S.; de Bono, J. S.; Gleave, M.; Zoubeidi, A.; Wouters, B. G.; Joshua, A. M.
CLINICAL CANCER RESEARCH 27(8):2340-2351, 2021
Advanced cancer patient wnowledge of and attitudes towards tumor molecular profiling
Davies, G.; Butow, P.; Napier, C. E.; Bartley, N.; Juraskova, I.; Meiser, B.; Ballinger, M. L.; Thomas, D. M.; Schlub, T. E.; Best, M. C.; members of the PiGeOn, Project.
Translational Oncology 13(9):100799, 2020
Cancer patients' views and understanding of genome sequencing: a qualitative study
Bartley, N.; Best, M.; Jacobs, C.; Juraskova, I.; Newson, A. J.; Savard, J.; Meiser, B.; Ballinger, M. L.; Thomas, D. M.; Biesecker, B.; Butow, P.
JOURNAL OF MEDICAL GENETICS 57(10):671-676, 2020
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities
Stacchiotti, S.; Frezza, A. M.; Blay, J. Y.; Baldini, E. H.; Bonvalot, S.; Bovee, Jvmg; Callegaro, D.; Casali, P. G.; Chiang, R. C.; Demetri, G. D.; Demicco, E. G.; Desai, J.; Eriksson, M.; Gelderblom, H.; George, S.; Gounder, M. M.; Gronchi, A.; Gupta, A.; Haas, R. L.; Hayes-Jardon, A.; Hohenberger, P.; Jones, K. B.; Jones, R. L.; Kasper, B.; Kawai, A.; Kirsch, D. G.; Kleinerman, E. S.; Le Cesne, A.; Lim, J.; Chirlaque Lopez, M. D.; Maestro, R.; Marcos-Gragera, R.; Martin Broto, J.; Matsuda, T.; Mir, O.; Patel, S. R.; Raut, C. P.; Razak, A. R. A.; Reed, D. R.; Rutkowski, P.; Sanfilippo, R. G.; Sbaraglia, M.; Schaefer, I. M.; Strauss, D. C.; Sundby Hall, K.; Tap, W. D.; Thomas, D. M.; van der Graaf, W. T. A.; van Houdt, W. J.; Visser, O.; von Mehren, M.; Wagner, A. J.; Wilky, B. A.; Won, Y. J.; Fletcher, C. D. M.; Dei Tos, A. P.; Trama, A.
CANCER 127(16):2934-2942, 2021
Is Li-Fraumeni syndrome really much more common?
Thomas, D. M.
HUMAN MUTATION 38(12):1619, 2017
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
Tap, W. D.; Gelderblom, H.; Palmerini, E.; Desai, J.; Bauer, S.; Blay, J. Y.; Alcindor, T.; Ganjoo, K.; Martin-Broto, J.; Ryan, C. W.; Thomas, D. M.; Peterfy, C.; Healey, J. H.; van de Sande, M.; Gelhorn, H. L.; Shuster, D. E.; Wang, Q.; Yver, A.; Hsu, H. H.; Lin, P. S.; Tong-Starksen, S.; Stacchiotti, S.; Wagner, A. J.
LANCET 394(10197):478-487, 2019
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; Investigators, Enzamet Trial; the, Australian; New Zealand, Urogenital; Prostate Cancer Trials, Group
EUROPEAN UROLOGY 80(3):275-279, 2021
Cancer patients' experiences with immune checkpoint modulators: A qualitative study
Ala-Leppilampi, K.; Baker, N. A.; McKillop, C.; Butler, M. O.; Siu, L. L.; Spreafico, A.; Abdul Razak, A. R.; Joshua, A. M.; Hogg, D.; Bedard, P. L.; Leighl, N.; Oza, A. M.; Parsons, J. A.; Hansen, A. R.
Cancer Medicine 9(9):3015-3022, 2020
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
Hamid, O.; Robert, C.; Daud, A.; Hodi, F. S.; Hwu, W. J.; Kefford, R.; Wolchok, J. D.; Hersey, P.; Joseph, R.; Weber, J. S.; Dronca, R.; Mitchell, T. C.; Patnaik, A.; Zarour, H. M.; Joshua, A. M.; Zhao, Q.; Jensen, E.; Ahsan, S.; Ibrahim, N.; Ribas, A.
Annals Of Oncology 30(4):582-588, 2019
The life history of neochromosomes revealed.
Papenfuss, A.T.; Thomas, D.M.
Surveillance recommendations for patients with germline TP53 mutations
Ballinger, M. L.; Mitchell, G.; Thomas, D. M.;
Who should access germline genome sequencing? A mixed methods study of patient views
Best, M. C.; Butow, P.; Jacobs, C.; Savard, J.; Biesecker, B.; Ballinger, M. L.; Bartley, N.; Davies, G.; Napier, C. E.; Smit, A. K.; Thomas, D. M.; Newson, A. J.; Members of the PiGeOn Project, .
CLINICAL GENETICS 97(2):329-337, 2020
Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing
Doble, B.; John, T.; Thomas, D.; Fellowes, A.; Fox, S.; Lorgelly, P.
LUNG CANCER 107:22-35, 2017
Developing a pan-cancer research autopsy programme
Bavi, P.; Siva, M.; Abi-Saab, T.; Chadwick, D.; Dhani, N.; Butany, J.; Joshua, A. M.; Roehrl, M. H.
Translational biology of osteosarcoma
Kansara, M.
; Teng, M. W.
; Smyth, M. J.
; Thomas, D. M.;
NATURE REVIEWS CANCER 14(11):722-35, 2014
Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counseling for hereditary cancer: a systematic review
Willis, A. M.; Smith, S. K.; Meiser, B.; Ballinger, M. L.; Thomas, D. M.; Young, M. A.
CLINICAL GENETICS 92(2):121-133, 2017
IFN-gamma is required for cytotoxic T cell-dependent cancer genome immunoediting
Takeda, K.; Nakayama, M.; Hayakawa, Y.; Kojima, Y.; Ikeda, H.; Imai, N.; Ogasawara, K.; Okumura, K.; Thomas, D. M.; Smyth, M. J.
Nature Communications 8:14607, 2017
Distinguishing activity from progress
Tattersall, M. H.
; Thomas, D. M.;
LANCET ONCOLOGY 16(16):1586-8, 2015
Infiltrating myeloid cells drive osteosarcoma progression via GRM4 regulation of IL23.
Kansara, M.; Thomson, K.; Pang, P.; Dutour, A.; Mirabello, L.; Acher, F.; Pin, J. P.; Demicco, E. G.; Yan, J.; Teng, M. W. L.; Smyth, M. J.; Thomas, D. M.
Cancer Discovery 9(11):1511-1519, 2019
The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly
Pinese, M.; Lacaze, P.; Rath, E.M.; Stone, A.; Brion, M.J.; Ameur, A.; Nagpal, S.; Puttick, C.; Husson, S.; Degrave, D.; Cristina, T.N.; Kahl, V.F.S.; Statham, A.L.; Woods, R.L.; McNeil, J.J.; Riaz, M.; Barr, M.; Nelson, M.R.; Reid, C.M.; Murray, A.M.; Shah, R.C.; Wolfe, R.; Atkins, J.R.; Fitzsimmons, C.; Cairns, H.M.; Green, M.J.; Carr, V.J.; Cowley, M.J.; Pickett, H.A.; James, P.A.; Powell, J.E.; Kaplan, W.; Gibson, G.; Gyllensten, U.; Cairns, M.J.; McNamara, M.; Dinger, M. E.; Thomas, D.M.
Nature Communications 11(1):435, 2020
The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design
Lacaze, P.; Pinese, M.; Kaplan, W.; Stone, A.; Brion, M. J.; Woods, R. L.; McNamara, M.; McNeil, J. J.; Dinger, M. E.; Thomas, D. M.
Translating genomic risk into an early detection strategy for sarcoma
Ballinger, M. L.; Pinese, M.; Thomas, D. M.
Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice
Leroy, B.; Ballinger, M. L.; Baran-Marszak, F.; Bond, G. L.; Braithwaite, A.; Concin, N.; Donehower, L. A.; El-Deiry, W. S.; Fenaux, P.; Gaidano, G.; Langerod, A.; Hellstrom-Lindberg, E.; Iggo, R.; Lehmann-Che, J.; Mai, P. L.; Malkin, D.; Moll, U. M.; Myers, J. N.; Nichols, K. E.; Pospisilova, S.; Ashton-Prolla, P.; Rossi, D.; Savage, S. A.; Strong, L. C.; Tonin, P. N.; Zeillinger, R.; Zenz, T.; Fraumeni, J. F., Jr.; Taschner, P. E.; Hainaut, P.; Soussi, T.
CANCER RESEARCH 77(6):1250-1260, 2017
Locally aggressive connective tissue tumors
Gounder, M. M.; Thomas, D. M.; Tap, W. D.
Health status, emergency department visits, and oncologists' feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trial
Sattar, S.; Alibhai, S. M. H.; Brennenstuhl, S.; Kulik, M.; MacDonald, M. E.; McWatters, K.; Lee, K.; Jang, R.; Amir, E.; Krzyzanowska, M. K.; Joshua, A. M.; Monette, J.; Wan-Chow-Wah, D.; Puts, M. T. E.
Journal of Geriatric Oncology 10(1):169-174, 2019
Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts
Jones, R. M.; Melton, P. E.; Pinese, M.; Rea, A. J.; Ingley, E.; Ballinger, M. L.; Wood, D. J.; Thomas, D. M.; Moses, E. K.
BMC Medical Genetics 20(1):69, 2019
Thyroid cancer clinicians' views and experiences of delayed treatment during the COVID-19 pandemic: An international cross-sectional survey
Nickel, B.; Miller, J. A.; Cvejic, E.; Gild, M. L.; Cope, D.; Dodd, R.; McCaffery, K.; Glover, A.
ANZ JOURNAL OF SURGERY 91(12):2562-2564, 2021
A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings
Rasmussen, V.; Forrest, L. E.; Rogasik, M.; Girodet, M.; Meeus, P.; Sunyach, M. P.; Blay, J. Y.; Bally, O.; Brahmi, M.; Ballinger, M. L.; Niedermayr, E.; Thomas, D. M.; Halliday, J.; James, P.; Ray-Coquard, I.; Young, M. A.; International Sarcoma Kindred, Study
Personalized Medicine 15(1):13-24, 2018
Refining the assessment and implications of AR-V7 in castrate-resistant prostate cancer
Crumbaker, M.; Savdie, R.; Joshua, A. M.
EUROPEAN UROLOGY 73(5):736-737, 2018
AR signaling and the PI3K pathway in prostate cancer
Crumbaker, M.; Khoja, L.; Joshua, A. M.
Cancers 9(4):34, 2017
UpFrontPSMA: a randomized phase 2 study of sequential (177) Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)
Dhiantravan, N.; Emmett, L.; Joshua, A. M.; Pattison, D. A.; Francis, R. J.; Williams, S.; Sandhu, S.; Davis, I. D.; Vela, I.; Neha, N.; Bressel, M.; Murphy, D. G.; Hofman, M. S.; Azad, A. A.
BJU International 128(3):331-342, 2021